New schizophrenia drug shows promise in early trial

NCT ID NCT07288333

Recruiting now Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times

Summary

This study tests a new drug called NBI-1117570 in 120 adults with schizophrenia who need hospital care. The goal is to see if it improves symptoms like hallucinations and disorganized thinking better than a placebo. Participants take the drug or a placebo daily for 35 days, and researchers measure changes using a standard symptom scale.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NBI-1117570
What this could lead to: If it works, this could point toward a new treatment option for schizophrenia that helps control symptoms during acute episodes.
What could go wrong: This is an early Phase 2a trial with only 120 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Neurocrine Clinical Site
RECRUITING

Kazanlak, 6100, Bulgaria
Neurocrine Clinical Site
RECRUITING

Pazardzhik, 4400, Bulgaria
Neurocrine Clinical Site
RECRUITING

Targovishte, 7700, Bulgaria
Neurocrine Clinical Site
RECRUITING

Târgu Mureş, 540136, Romania
Neurocrine Clinical Site
RECRUITING

London, SE5 8AZ, United Kingdom
Neurocrine Clinical Site
RECRUITING

Oxford, OX3 7JX, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.